Catalyst
Slingshot members are tracking this event:
FDA Will Review BioMarin's (BMRN) New Drug Application for Duchenne Muscular Dystrophy Candidate Drisapersen on November 24, 2015
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 24, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Adcom, Drisapersen, Dmd, Duchenne Muscular Dystrophy
